Achieving PSA < 0.2 ngml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer
Joint Authors
Hara, Noboru
Kazama, Akira
Saito, Toshihiro
Takeda, Keisuke
Kobayashi, Kazuhiro
Tanikawa, Toshiki
Kanemoto, Ayae
Ayukawa, Fumio
Matsumoto, Yasuo
Sugita, Tadashi
Tomita, Yoshihiko
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-10-17
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Background.
To predict long-term treatment outcome of radiation therapy (RT) plus androgen deprivation therapy (ADT) for high-risk locally advanced prostate cancer.
Methods.
In total, 204 patients with the National Comprehensive Cancer Network (NCCN) high risk locally advanced prostate cancer (PSA > 20 ng/ml, Gleason score ≧ 8, clinical T stage ≧ 3a) were treated with definitive RT with ADT.
Median follow up period was 113 months (IQR: 95–128).
Median neoadjuvant ADT and total ADT duration were 7 months (IQR: 6–10) and 27 months (IQR: 14–38), respectively.
Results.
PSA recurrence-free survival (PSA-RFS), cancer specific survival (CSS), and overall survival (OS) rates at 5 years were 84.1%, 98.5%, and 93.6%, respectively, and 67.9%, 91.2%, and 78.1%, respectively, at 10 years.
Pre-RT PSA less than 0.2 ng/ml was associated with superior outcomes of PSA-RFS (HR = 0.42, 95% CI: 0.25–0.70, p=0.001), CSS (HR = 0.27, 95% CI: 0.09–0.82, p=0.013), and OS (HR = 0.48, 95% CI: 0.26–0.91, p=0.021).
On multivariate analysis, age (≥70 y.o.) and pre-RT PSA (≥0.2 ng/ml) were factors predictive of poorer OS (p=0.032) , but iPSA, T stage, Gleason score, number of NCCN high-risk criteria, a combination with anti-androgen therapy and neoadjuvant ADT duration were not predictive of treatment outcome.
Conclusion.
In patient with high-risk prostate cancer, RT plus ADT achieved good oncologic outcomes.
PSA < 0.2 ng/ml before radiation therapy is a strong independent predictor for long overall survival.
American Psychological Association (APA)
Kazama, Akira& Saito, Toshihiro& Takeda, Keisuke& Kobayashi, Kazuhiro& Tanikawa, Toshiki& Kanemoto, Ayae…[et al.]. 2019. Achieving PSA < 0.2 ngml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer. Prostate Cancer،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1206797
Modern Language Association (MLA)
Kazama, Akira…[et al.]. Achieving PSA < 0.2 ngml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer. Prostate Cancer No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1206797
American Medical Association (AMA)
Kazama, Akira& Saito, Toshihiro& Takeda, Keisuke& Kobayashi, Kazuhiro& Tanikawa, Toshiki& Kanemoto, Ayae…[et al.]. Achieving PSA < 0.2 ngml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer. Prostate Cancer. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1206797
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1206797